Novartis lung drug not inferior to GSK's Seretide, study shows

ZURICH (Reuters) - Patients taking Novartis' inhaled medicine Onbrez Breezhaler for chronic lung disease had benefits similar to those taking GlaxoSmithKline's Seretide, the Swiss drugmaker said on Friday, citing a late stage study. Also known as QVA149, Onbrez Breezhaler belongs to a new type of dual-action treatments that are expected by analysts to become major sellers. ...

via Health News Headlines - Yahoo News http://ift.tt/1pw1voU